Cargando…

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

Bromodomains (BRDs) are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. The 61 BRDs in the human genome cluster into eight families based on structure/sequence similarity. Here, we present 29 high-resoluti...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippakopoulos, Panagis, Picaud, Sarah, Mangos, Maria, Keates, Tracy, Lambert, Jean-Philippe, Barsyte-Lovejoy, Dalia, Felletar, Ildiko, Volkmer, Rudolf, Müller, Susanne, Pawson, Tony, Gingras, Anne-Claude, Arrowsmith, Cheryl H., Knapp, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326523/
https://www.ncbi.nlm.nih.gov/pubmed/22464331
http://dx.doi.org/10.1016/j.cell.2012.02.013
Descripción
Sumario:Bromodomains (BRDs) are protein interaction modules that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. The 61 BRDs in the human genome cluster into eight families based on structure/sequence similarity. Here, we present 29 high-resolution crystal structures, covering all BRD families. Comprehensive crossfamily structural analysis identifies conserved and family-specific structural features that are necessary for specific acetylation-dependent substrate recognition. Screening of more than 30 representative BRDs against systematic histone-peptide arrays identifies new BRD substrates and reveals a strong influence of flanking posttranslational modifications, such as acetylation and phosphorylation, suggesting that BRDs recognize combinations of marks rather than singly acetylated sequences. We further uncovered a structural mechanism for the simultaneous binding and recognition of diverse diacetyl-containing peptides by BRD4. These data provide a foundation for structure-based drug design of specific inhibitors for this emerging target family.